Navigation Links
Researchers find safer way to use common but potentially dangerous medication
Date:2/29/2012

SALT LAKE CITY A team of global scientists, led by researchers at Intermountain Medical Center in Salt Lake City, has developed a safer and more accurate way to administer warfarin, one of the most commonly prescribed but also potentially dangerous medications in the United States.

As part of a worldwide study, the research team developed and tested a new formula that combines individual genetic data with a mathematical model to help physicians more accurately predict patient response to the popular blood-thinning drug.

Researchers found that the formula was safer and more accurate than current methods used to dose for warfarin patients. They're hopeful that the more accurate dosing will eliminate many emergency hospitalizations among warfarin users. Results of the team's study are published in the February edition of the journal, Thrombosis and Haemostasis.

Every year, more than two million Americans begin taking warfarin after joint replacement surgery or who have heart rhythm disorders, stroke risk, deep vein thrombosis, or other common conditions. Because patient response to the drug is so variable, it's difficult for physicians to determine safe, yet effective dosages for each individual.

The consequences can be serious: If patients get too much warfarin, they can develop uncontrolled bleeding; too little and they can suffer a stroke or a blood clot in another location.

"Physicians usually test a patient's blood once or twice in the first week after starting warfarin to see if it's clotting properly," said Benjamin Horne, PhD, director of genetic epidemiology at the Intermountain Medical Center Heart Institute and lead author of the study. "But we've shown that because of genetic variation, patient response to warfarin continues to change after the first week and dosing may need to change, too."

The research group, comprised of physicians and scientists at 13 centers in the United States, Europe, and Asia, tracked 1,342 patients on days six through 11 after beginning treatment with warfarin. The team considered factors such as individual body mass index, medication usage, age, gender, and whether or not the patients carried two genes that are known to influence the way warfarin affects the body.

From those data, Dr. Horne and his colleagues were able to create a mathematical model to predict individual patient response to warfarin. The group applied their new algorithm to 342 different patients to validate that it could accurately predict patient response to the drug and help determine more appropriate dosages.

"We discovered that the algorithm is significantly more precise and accurate in identifying the best dose for an individual patient," said Dr. Horne.

He said the body's response to warfarin stabilizes after the second week of treatment, and that the algorithm can determine the safest dose possible for the full course of warfarin treatment. Researchers believe future studies will demonstrate the financial, as well as clinical, benefits of conducting genetic tests needed to perfect the dosing for individual patients.

"This is a very hopeful first step in that direction," said Dr. Horne. "I expect we'll see more studies in the future that show the real effect this tool will have on the lives of patients."

The algorithm is the latest research on genetics and warfarin dosing at Intermountain Medical Center. An earlier project, led by Intermountain Heart Institute cardiologist Jeffrey L. Anderson, MD, examined the effectiveness of genetic testing on warfarin use.

Both group's findings are being used to build a computer tool that works within Intermountain Healthcare's electronic medical record system and that will perform warfarin calculations automatically, thereby increasing patient safety.

"This promises to be a powerful tool to tailor warfarin dosing to each individual patient," said Scott C. Woller, MD, an internal medicine specialist at Intermountain Medical Center who is helping to create the computer system. "The goal of this effort is to make patient-specific dosing algorithms as accessible as possible to busy clinicians."


'/>"/>

Contact: Jess C. Gomez
jess.gomez@imail.org
801-507-7455
Intermountain Medical Center
Source:Eurekalert

Related biology news :

1. SFU researchers help discover new HIV vaccine-related tool
2. Notre Dame researchers are providing insights into elephant behavior and conservation issues
3. Researchers develop worlds first biodegradable joint implant
4. Researchers identify novel pathway responsible for infection of a common STD pathogen
5. Researchers discover how vitamin D inhibits inflammation
6. Purdue researchers reveal role of protein mutation in Parkinsons disease
7. UVic researchers among presenters at global science conference
8. Researchers develop better control for DNA-based computations
9. Researchers warn nanoparticles in food, vitamins could harm human health
10. Worlds top technology researchers coming to Queens for TEI 2012
11. Researchers make living model of brain tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/17/2016)... March 17, 2016 ABI Research, the ... the global biometrics market will reach more than ... increase from 2015. Consumer electronics, particularly smartphones, continue ... sensors anticipated to reach two billion shipments by ... Dimitrios Pavlakis , Research Analyst at ABI Research. ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice ... surgery and surgery of the hand by the National Board of Physicians and ... above and beyond in his pursuit of providing the most comprehensive, effective treatment ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across the ... Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations across ... down 21 percent in South Texas in the last four years alone. , There is ...
(Date:5/23/2016)... Springs, North Carolina (PRWEB) , ... May 23, ... ... process automation and building management solutions and services based in Aurora, Ohio, has ... decade of established business in the Research Triangle Park area, this new location ...
Breaking Biology Technology: